Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

May 1, 2006

Primary Completion Date

April 15, 2011

Study Completion Date

June 20, 2016

Conditions
Breast Cancer
Interventions
DRUG

gemcitabine hydrochloride

Given IV

DRUG

imatinib mesylate

Given orally

Trial Locations (9)

21201

University of Maryland Greenebaum Cancer Center, Baltimore

60611-3013

Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago

08103

Cooper Hospital/University Medical Center, Camden

08690

Rutgers Cancer Institute of New Jersey at Hamilton, Hamilton

07042

Mountainside Hospital, Montclair

07754

Jersey Shore Cancer Center at Jersey Shore University Medical Center, Neptune City

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

Saint Peter's University Hospital, New Brunswick

07103

NJ Medical School, Newark

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Novartis Pharmaceuticals

INDUSTRY

collaborator

Rutgers Cancer Institute of New Jersey

OTHER

lead

Rutgers, The State University of New Jersey

OTHER